- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug alert: 35 drug samples fail to clear CDSCO test, 1 declared spurious
Overview
In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 35 medicine batches for failing to qualify for random drug sample tests for the month of April, while one drug sample has been declared spurious.
These drugs samples which are declared not of standard quality include Skymap Pharmaceuticals' Metopal – 50 XL (Metoprolol Succinate Extended Release Tablets IP), Alkem Health Science's Pantoprazole gastro- resistant and domperidone prolonged-release capsules IP Pan-D, Zee laboratories' Paracetamol oral suspension IP 60 ml. (for Paediatric use), Hindustan Antibiotic's Diclofenac Sodium Injection and others.
For more details, check out the link given below:
Drug alert:35 Drug Samples Fail To Clear CDSCO Test, 1 Declared spurious